Skip to Main Content

Paper Details

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
J Clin Oncol
122
2017
Bortezomib, Cell Lymphoma, DLBCL, GCB DLBCL, Non-Germinal Center B-Cell-Like Diffuse Large B-, Patients, VR, VR-CHOP, anemia, bortezomib, cyclophosphamide, doxorubicin, leukopenia, neuropathy, neutropenia, non, non-, non-GCB DLBCL, non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma, patients, prednisone, rituximab, thrombocytopenia, vincristine
Author NameAffiliation
Robert H CollinsWeill Cornell Medicine and New York Presbyterian Hospital, University of Texas Southwestern Medical Center, University of Florida Health Cancer Center at Orlando Health, Keck Medicine of University of Southern California Sven de Vos, University of California at Los Angeles Jonsson Comprehensive Cancer Center, Kaiser Permanente Medical Center Northern California, Sarah Cannon Research Institute, Winship Cancer Institute of Emory University, Rocky Mountain Cancer Centers, Summit Medical Group MD Anderson Cancer Center, Rush University Medical Center, York Cancer Center/Cancer Care Associates of York, Millennium Pharmaceuticals
George MulliganWeill Cornell Medicine and New York Presbyterian Hospital, University of Texas Southwestern Medical Center, University of Florida Health Cancer Center at Orlando Health, Keck Medicine of University of Southern California Sven de Vos, University of California at Los Angeles Jonsson Comprehensive Cancer Center, Kaiser Permanente Medical Center Northern California, Sarah Cannon Research Institute, Winship Cancer Institute of Emory University, Rocky Mountain Cancer Centers, Summit Medical Group MD Anderson Cancer Center, Rush University Medical Center, York Cancer Center/Cancer Care Associates of York, Millennium Pharmaceuticals
  • 1 - 2

Datasets

Release 1.2